Arch Oncology

Arch Oncology

Biotechnology, 2000 Sierra Pt Pkwy Fl 700, Brisbane, California, 94005, United States, 11-50 Employees

archoncology.com

  • LinkedIn

Who is ARCH ONCOLOGY

Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with s...

Read More

map
  • 2000 Sierra Pt Pkwy Fl 700, Brisbane, California, 94005, United States Headquarters: 2000 Sierra Pt Pkwy Fl 700, Brisbane, California, 94005, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from ARCH ONCOLOGY

Arch Oncology Org Chart and Mapping

Employees

Carrie Brachmann

Vice President, Translational Medicine

Kevin Romanko

Vice President Clinical Operations

Robyn Puro

Director of Research

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Arch Oncology

Answer: Arch Oncology's headquarters are located at 2000 Sierra Pt Pkwy Fl 700, Brisbane, California, 94005, United States

Answer: Arch Oncology's official website is https://archoncology.com

Answer: Arch Oncology's revenue is $5 Million to $10 Million

Answer: Arch Oncology's SIC: 8731

Answer: Arch Oncology has 11-50 employees

Answer: Arch Oncology is in Biotechnology

Answer: Arch Oncology contact info: Phone number: Website: https://archoncology.com

Answer: Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies. Our lead product candidate AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with multiple myeloma, both as monotherapy and in combination with standard therapies. In addition, we are advancing a pipeline of antibody programs for the treatment of cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. AO-176 works by blocking the dont eat me signal for macrophages, the standard mechanism of anti-CD47 antibodies. However, beyond blocking this signal, AO-176 has additional mechanisms including both directly killing tumor cells and inducing DAMPs (Damage Associated Molecular Patterns) resulting in Immunogenic Cell Death. Importantly, AO-176 binds preferentially to CD47 on tumor cells, instead of normal cells, and binds even more potently in low pH conditions such as the tumor microenvironment. Our headquarters is in Brisbane, CA, a gateway of biotechnology innovation, and our scientific research laboratory is in St. Louis, MO, home of the Gateway Arch.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access